Skip to content

APPEND-CT Registry

Cardiac Computed Tomography Following Watchman FLX Left Atrial APPENDage Closure

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06213285
Acronym
APPEND-CT
Enrollment
2000
Registered
2024-01-19
Start date
2024-02-14
Completion date
2025-01-31
Last updated
2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Device Related Thrombosis, Stroke, Ischemic

Keywords

Left Atrial Appendage Occlusion, Cardiac Computed Tomography, Watchman FLX

Brief summary

The APPEND-CT registry is an investigator-driven multicenter retrospective observational database intended to compile cardiac CT follow-up data after Watchman FLX device implantation and function as a platform for answering clinical and research questions within LAAC follow-up. The derived studies should support therapeutic decision-making, improve risk-stratification in LAAC and help generate hypotheses for potential future clinical intervention trials.

Detailed description

An investigator-driven multicenter retrospective observational database enrolling patients from high-volume North American and European centers. The database will include Watchman FLX implanted patients with a minimum of one follow-up cardiac CT performed within 45-120 days post-procedure. Additional timepoints may be entered. Cardiac CT scans are to be uploaded and will be analyzed by the core-lab at Aarhus University Hospital. Investigator-reported findings will be systematically reported to the database. This includes information on baseline characteristics, preprocedural planning, implantation details, discharge medication, follow-up imaging and clinical endpoints of interest. As a minimum, investigator-reported endpoints will be collected from patient registries at one-year follow-up by site-investigators. Endpoints of interest include ischemic stroke, systemic embolism, major bleeding, mortality, device-related thrombosis, pericardial effusion, vascular complications, and device migration.

Interventions

DEVICEWatchman FLX left atrial appendage occlusion

Early (30-120 days) CT follow-up after Watchman FLX LAAO

Sponsors

Mayo Clinic
CollaboratorOTHER
Boston Scientific Corporation
CollaboratorINDUSTRY
Aarhus University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Watchman FLX LAAO * A minimum of one follow-up cardiac CT performed within 30-120 days post-procedure. * A minimum of one year clinical follow-up data

Design outcomes

Primary

MeasureTime frameDescription
Ischemic strokeMinimum 12 monthsClinically affirmed ischemic stroke

Secondary

MeasureTime frameDescription
Device-related thrombosisMinimum 12 monthsHigh-grade hypoattenuated thickening as seen on cardiac CT
Major bleedingMinimum 12 monthsBARC \>=2
All-cause and cardiovascular mortalityMinimum 12 monthsAs defined in the Munich consensus

Countries

Denmark, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026